The University of Texas System

Geron Corporation

Other

Advanced Cell Technology, Inc.

University of California

Biotime, Inc.

Agex Therapeutics, Inc.

Lineage Cell Therapeutics, Inc.

Reverse Bioengineering, Inc.

Cornell Research Foundation Inc.

Sanford-burnham Medical Research Institute

Astellas Institute for Regenerative Medicine

Mandala Biosciences, LLC

Geron Corporation & Board of Regents

Advance Cell Technology, Inc.

Michael D West

Jerry W Shay

Woodring E Wright

Karen B Chapman

Hal Sternberg

Calvin B Harley

Elizabeth H Blackburn

Robert P Lanza

Scott L Weinrich

Michael J McEachern

Nam Woo Kim

Jose Cibelli

Homayoun Vaziri

Catherine M Strahl

Irina V Klimanskaya

Joseph D Gold

Walter D Funk

Margaret Inokuma

Evan Y Snyder

James T Murai

Damian L Lang

Choy-Pik Chiu

Andrea G Bodnar

Karen Chapman

Nam Hoon Kim

Shahin Rafii

Bryant Villeponteau

Junli Feng

Young Gie Chung

David Larocca

Jay M Edelberg

Dana Larocca

Raymond L Page

Paola A Bignone

Hans R Schoeler

Maarten H Linskens

Stanley T Carmichael

Roy Geoffrey Sargent

Mun K Hong

Andrew N Clarkson

Hans Scholer

Kenneth S Hirsch

Paola Bignone

Raymond Page

Aspects of the present invention include methods and compositions related to the modulation of molecules regulating the regenerative potential of cells and tissues in the embryonic state and the loss thereof in later fetal and adult stages of development. The methods and compositions have uses in research in stem cell biology and in increasing regenerative potential in fetal and adult tissues otherwise incapable of regeneration.

Compositions and methods for induced tissue regeneration in mammalian species

Aspects of the present invention include methods and compositions related to the modulation of molecules regulating the regenerative potential of cells and tissues in the embryonic state and the loss thereof in later fetal and adult stages of development. Said methods and compositions have uses in research in stem cell biology and in increasing regenerative potential in fetal and adult tissues otherwise incapable of regeneration.

Aspects of the present invention include methods and compositions related to the production and use of pluripotent stem cell-derived clonal embryonic progenitor cell types useful in the generation of cellular components of brown adipocyte tissue for research and therapy relating to applications in obesity, diabetes, and cardiovascular disease.

Methods for the re-derivation of diverse pluripotent stem cell-derived brown fat cells

Aspects of the present invention include methods and compositions related to the production and use of numerous clonal lineages of embryonic progenitor cell lines derived from differentiating cultures of primordial stem cells with diverse molecular markers and having been cultured for &#x3e;21 doublings of clonal expansion. The robustness of these clonally-purified lines, their ability to expand for &#x3e;40 passages while maintaining their pattern of gene expression, lack of tumorigenicity, and their embryonic pattern of gene expression offers novel compositions and methods for modeling numerous differentiation pathways for the first time in vitro, and for the manufacture of purified product not existing in such a purified state in nature or using other manufacturing modalities. Representative progenitor cell lines described herein are capable of development into cutaneous adipocytes, blood-brain barrier cells, neuronal cells, or smooth muscle cells each with therapeutic potential.

Methods of screening embryonic progenitor cell lines

Aspects of the present invention include methods and compositions related to the production and use of clonal lineages of embryonic progenitor cell lines derived from differentiating cultures of primordial stem cells, in particular, said methods and compositions relate to methods of differentiating cells in the presence of members of the BMP family of growth factors and the applications of said cell lines in the treatment of degenerative orthopedic diseases such as osteoarthritis.

Methods and formulations for orthopedic cell therapy

The generation of clinical-grade cell-based therapies from human embryonic stein cells or cells reprogrammed to pluripotency from somatic cells, requires stringent quality controls to insure that the cells have long enough telomeres and resulting cellular lifespan to be clinically useful, and normal gene expression and genomic integrity so as to insure cells with a desired and reproducible phenotype and to reduce the risk of the malignant transformation of cells. Assays useful in identifying human embryonic stem cell lines and pluripotent cells resulting from the transcriptional reprogramming of somatic cells that have embryonic telomere length are described as well as quality control assays for screening genomic integrity in cells expanded and banked for therapeutic use, as well as assays to identify cells capable of abnormal immortalization.

Methods for telomere length and genomic DNA quality control analysis in pluripotent stem cells

This invention generally relates to methods to obtain mammalian cells and tissues with patterns of gene expression similar to that of a developing mammalian embryo or fetus, and the use of such cells and tissues in the treatment of human disease and age-related conditions. More particularly, the invention relates to methods for identifying, expanding in culture, and formulating mammalian pluripotent stem cells and differentiated cells that differ from cells in the adult human in their pattern of gene expression, and therefore offer unique characteristics that provide novel therapeutic strategies in the treatment of degenerative disease.

Methods of reprogramming animal somatic cells

The invention provides methods, compositions and kits for the identification and enrichment of progenitor cell lines obtained from pluripotent stem cells.

Methods and compositions for targeting progenitor cell lines

Methods for producing stem cell banks, preferably human, which optionally may be transgenic, e.g., comprised of homozygous MHC allele cell lines are provided. These cells are produced preferably from parthenogenic, IVF, or same-species or cross-species nuclear transfer embryos or by dedifferentiation of somatic cells by cytoplasm transfer. Methods for using these stem cell banks for producing stem and differentiated cells for therapy, especially acute therapies, and for screening for drugs for disease treatment are also provided.

Bank of stem cells for producing cells for transplantation having HLA antigens matching those of transplant recipients, and methods for making and using such a stem cell bank

The vast differentiation potential of human embryonic and induced pluripotent stem cells, including their potential to cascade through all of the somatic cell lineages and to display the complete transcriptional regulatory network of human biology, has generated interest in deriving scalable, purified, and identified cell types and methods of discovering the precise structure of the human regulatory network. However, the innate capacity of pluripotent cells to display all these lineages is not necessarily reflected during their culture in vitro. The clonal isolation and propagation of progenitors greatly facilitates the generation of highly purified and identified formulations for research and therapeutic purposes. Nevertheless, other cell types have yet to be isolated and propagated from normal cells and methods of isolating said novel cell types as well as methods for introducing perturbations into the transcriptional regulatory network in order to construct a computer model of the entire human transcriptional regulatory network would greatly benefit basic research as well as manufacturing technology for cell-based therapies.

Methods of modifying transcriptional regulatory networks in stem cells

The invention relates to assays for screening growth factors, adhesion molecules, immunostimulatory molecules, extracellular matrix components and other materials, alone or in combination, simultaneously or temporally, for the ability to induce directed differentiation of pluripotent and multipotent stem cells.

Differentiating ES cells using a tenascin

An improved method of producing differentiated progenitor cells comprising obtaining inner cell mass cells from a blastocyst and inducing differentiation of the inner cell mass cells to produce differentiated progenitor cells. The differentiated progenitor cells may be transfected such that there is an addition, deletion or alteration of a desired gene. The differentiated progenitor cells are useful in cell therapy and as a I source of cells for the production of tissues and organs for transplantation. Also provided is a method of producing a lineage-defective human embryonic stem cell.

Method of differentiation of morula or inner cell mass cells and method of making lineage-defective embryonic stem cells

Aspects of the present invention include methods and compositions related to the production, identification and use of embryonic progenitor cell lines that are capable of undergoing chondrogenesis. A number of exemplary chondrogenic cell lines derived from primordial stem cells are disclosed. The chondrogenic cell lines described herein are robust, can expand for &#x3e;40 passages, and have site-specific purity, thus providing for compositions and methods of producing diverse cartilage types with unique molecular compositions for use in research and therapy.

Methods and compositions for in vitro and in vivo chondrogenesis

Growing community of inventors

Mill Valley, CA, United States of America

Michael D West